Natures Sunshine Products Q4 2023 Adj EPS $0.45 Beats $0.15 Estimate, Sales $108.936M Miss $111.133M Estimate

3/12/24 4:16:37 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NATR alert in real time by email

Natures Sunshine Products (NASDAQ:NATR) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.15 by 200 percent. The company reported quarterly sales of $108.936 million which missed the analyst consensus estimate of $111.133 million by 1.98 percent. This is a 6.02 percent increase over sales of $102.749 million the same period last year.

Get the next $NATR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NATR

Date	Price Target	Rating	Analyst
9/13/2024	$18.00	Buy	Canaccord Genuity
3/9/2022	$24.00 → $24.50	Buy	DA Davidson
11/5/2021	$22.00 → $24.00	Buy	DA Davidson
10/15/2021	$22.00	Buy	DA Davidson

More analyst ratings

$NATR
Press Releases

Fastest customizable press release news feed in the world

Nature's Sunshine Appoints Steven Fasching to Board of Directors
LEHI, Utah, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Mr. Steven Fasching to its board of directors, effective November 6, 2024. Nature's Sunshine's board will now consist of nine directors with eight serving as independent directors. "We are delighted to welcome Steve to our expanded board of directors," said Richard D. Moss, Chairman of the Board for Nature's Sunshine. "He brings significant financial acumen and public company experience from well-known consumer brands and will be a valuable addition to our board. Ste
11/11/24 4:05:00 PM ET
$DECK
$NATR
Shoe Manufacturing
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Nature's Sunshine Reports Third Quarter 2024 Results
LEHI, Utah, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading natural health and wellness company offering high-quality herbal and nutritional products, reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were up 3% to $114.6 million compared to $111.2 million (up 4% in constant currency).GAAP net income attributable to common shareholders was $4.3 million, or $0.23 per diluted common share, compared to $2.8 million, or $0.15 per diluted common share.Adjusted EBITDA was up 5% to $10.7 million compared to $10.3 million. Management
11/7/24 4:05:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care
Nature's Sunshine Sets Third Quarter 2024 Conference Call for Thursday, November 7, 2024, at 5:00 p.m. ET
LEHI, Utah, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading natural health and wellness company offering high-quality herbal and nutritional products, will conduct a conference call on Thursday, November 7, 2024, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the third quarter ended September 30, 2024. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, November 7, 2024Time: 5:00 p.m. Eastern t
10/24/24 4:05:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care

$NATR
Financials

Live finance-specific insights

Nature's Sunshine Reports Third Quarter 2024 Results
LEHI, Utah, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading natural health and wellness company offering high-quality herbal and nutritional products, reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were up 3% to $114.6 million compared to $111.2 million (up 4% in constant currency).GAAP net income attributable to common shareholders was $4.3 million, or $0.23 per diluted common share, compared to $2.8 million, or $0.15 per diluted common share.Adjusted EBITDA was up 5% to $10.7 million compared to $10.3 million. Management
11/7/24 4:05:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care
Nature's Sunshine Sets Third Quarter 2024 Conference Call for Thursday, November 7, 2024, at 5:00 p.m. ET
LEHI, Utah, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading natural health and wellness company offering high-quality herbal and nutritional products, will conduct a conference call on Thursday, November 7, 2024, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the third quarter ended September 30, 2024. The company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Terrence Moorehead and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Thursday, November 7, 2024Time: 5:00 p.m. Eastern t
10/24/24 4:05:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care
Nature's Sunshine Reports Second Quarter 2024 Results
LEHI, Utah, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading natural health and wellness company of high-quality herbal and nutritional products, reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Summary vs. Same Year-Ago Quarter Net sales were down 5% to $110.6 million compared to $116.5 million (down 3% in constant currency).Gross margin decreased 125 basis points to 71.4% compared to 72.6%.GAAP net income attributable to common shareholders was $1.3 million, or $0.07 per diluted common share, compared to $2.4 million, or $0.12 per diluted common share.Adjusted EBITDA down
8/8/24 4:05:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care

Nature's Sunshine Appoints Steven Fasching to Board of Directors
LEHI, Utah, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Mr. Steven Fasching to its board of directors, effective November 6, 2024. Nature's Sunshine's board will now consist of nine directors with eight serving as independent directors. "We are delighted to welcome Steve to our expanded board of directors," said Richard D. Moss, Chairman of the Board for Nature's Sunshine. "He brings significant financial acumen and public company experience from well-known consumer brands and will be a valuable addition to our board. Ste
11/11/24 4:05:00 PM ET
$DECK
$NATR
Shoe Manufacturing
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Nature's Sunshine Names Kevin Fuller Global Chief Marketing Officer
LEHI, Utah, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Kevin Fuller as Global Chief Marketing Officer, effective September 23, 2024. Fuller, a seasoned marketing executive with over two decades of experience in high-performance organizations, brings in-depth global marketing experience to Nature's Sunshine. His deep understanding of the dietary supplement industry combined with his experience launching new products, building powerful brands, and driving customer growth strategies make Fuller an ideal fit for Nature's Sunshine. "We are ver
9/16/24 2:00:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care
Nature's Sunshine Announces Retirement of CFO Joseph Baty
Jonathon Lanoy to Serve as Interim CFO LEHI, Utah, Sept. 6, 2022 /PRNewswire/ -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) (Nature's Sunshine), a leading natural health and wellness company of high-quality herbal and nutritional products, today announced the retirement from the company of its Chief Financial Officer Joseph Baty, effective September 30, 2022. Nature's Sunshine has engaged a leading executive search firm to find its next CFO. Jonathan Lanoy, the company's Corporate Controller and Vice President of Finance, will serve as interim CFO, principal financial offi
9/6/22 5:00:00 PM ET
$NATR
Biotechnology: Pharmaceutical Preparations
Health Care

Natures Sunshine Products Q4 2023 Adj EPS $0.45 Beats $0.15 Estimate, Sales $108.936M Miss $111.133M Estimate

Chat with this insight

Recent Analyst Ratings for $NATR

$NATR Press Releases

Fastest customizable press release news feed in the world

Nature's Sunshine Appoints Steven Fasching to Board of Directors

Nature's Sunshine Reports Third Quarter 2024 Results

Nature's Sunshine Sets Third Quarter 2024 Conference Call for Thursday, November 7, 2024, at 5:00 p.m. ET

$NATR SEC Filings

SEC Form 10-Q filed by Nature's Sunshine Products Inc.

Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$NATR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

$NATR Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

$NATR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Fasching Steven J. was granted 2,869 shares (SEC Form 4)

SEC Form 3 filed by new insider Fasching Steven J.

Large owner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. sold $29,946 worth of shares (2,300 units at $13.02) (SEC Form 4)

$NATR Financials

Live finance-specific insights

Nature's Sunshine Reports Third Quarter 2024 Results

Nature's Sunshine Sets Third Quarter 2024 Conference Call for Thursday, November 7, 2024, at 5:00 p.m. ET

Nature's Sunshine Reports Second Quarter 2024 Results

$NATR Market Insights

Live Market Insights

$NATR Leadership Updates

Live Leadership Updates

Nature's Sunshine shares are trading lower after the company reported worse-than-expected Q1 financial results.

Natures Sunshine Products Sees FY24 Net Sales $455M-$480M Vs $467.900M Est.

Natures Sunshine Products Q1 2024 Adj EPS $0.12 Misses $0.17 Estimate, Sales $110.993M Miss $111.200M Estimate

Nature's Sunshine Appoints Steven Fasching to Board of Directors

Nature's Sunshine Names Kevin Fuller Global Chief Marketing Officer

Nature's Sunshine Announces Retirement of CFO Joseph Baty

Recent Analyst Ratings for
$NATR

$NATR
Press Releases

$NATR
SEC Filings

$NATR
Analyst Ratings

$NATR
Large Ownership Changes

$NATR
Insider Trading

$NATR
Financials

$NATR
Market Insights

$NATR
Leadership Updates